Linked Life Data

2087823

Source:http://linkedlifedata.com/resource/pubmed/id/2087823

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1991-5-23
pubmed:abstractText
In the last decade radioimmunoscintigraphy developed from an experimental approach to a clinically useful method. First promising results were obtained with Technetium-99m labelled murine monoclonal antibodies against carcinoembryonic antigen (CEA). Routine clinical application is restricted to colorectal carcinoma at the moment. Radioimmunoscintigraphy is recommended in case of recurring disease when conventional methods are ineffective or doubtful, especially in the pelvic region. The availability of monoclonal antibodies to new tumor-associated antigens will extend the spectrum to other gastrointestinal tumors. The possibility to generate recombinant humanized monoclonal antibodies and antibody fragments are encouraging new perspectives. These developments and the use of biological immune response modifiers to increase antigen expression could provide means to consider radioimmunotherapy of gastrointestinal cancers.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0044-2771
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
673-7
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
[Immunoscintigraphy in colorectal cancers from the viewpoint of the gastroenterologist].
pubmed:affiliation
I. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz, Bundesrepublik Deutschland.
pubmed:publicationType
Journal Article, English Abstract, Review